PDGFRA and sarcoma: Finally, as a standard of care drug in sarcoma and renal carcinoma pazopanib is dosed daily and would thus be likely to block any compensatory survival signaling through PDGFRα/PDGFRβ/FGFR, but not through c-MET or SRC-linked cytokine receptors.